Stephen K. Doberstein
2017
In 2017, Stephen K. Doberstein earned a total compensation of $7.7M as Senior Vice President and Chief Research and Development Officer at Nektar Therapeutics, a 347% increase compared to previous year.
Compensation breakdown
| Non-Equity Incentive Plan | $525,000 |
|---|---|
| Option Awards | $3,672,084 |
| Salary | $529,084 |
| Stock Awards | $2,958,794 |
| Other | $13,988 |
| Total | $7,698,950 |
Doberstein received $3.7M in option awards, accounting for 48% of the total pay in 2017.
Doberstein also received $525K in non-equity incentive plan, $529.1K in salary, $3M in stock awards and $14K in other compensation.
Rankings
In 2017, Stephen K. Doberstein's compensation ranked 1,016th out of 14,666 executives tracked by ExecPay. In other words, Doberstein earned more than 93.1% of executives.
| Classification | Ranking | Percentile |
|---|---|---|
All | 1,016 out of 14,666 | 93rd |
Division Manufacturing | 345 out of 5,770 | 94th |
Major group Chemicals And Allied Products | 90 out of 2,074 | 96th |
Industry group Drugs | 59 out of 1,730 | 97th |
Industry Pharmaceutical Preparations | 49 out of 1,329 | 96th |
Source: SEC filing on April 30, 2018.
Doberstein's colleagues
We found four more compensation records of executives who worked with Stephen K. Doberstein at Nektar Therapeutics in 2017.
2017
Howard Robin
Nektar Therapeutics
Chief Executive Officer
2017
John Nicholson
Nektar Therapeutics
Chief Operating Officer
2017
Gil Labrucherie
Nektar Therapeutics
Chief Financial Officer
2017
Maninder Hora
Nektar Therapeutics